{"paper_id":"66631974-3270-46ae-8375-ebbc073777e4","body_text":"Abstract\nBackground\nEndometrioid borderline ovarian tumor (EBOT) is a rare subtype of borderline ovarian malignancies. This study was designed to determine the prognosis of a series of EBOT.\nMethods\nThis is a retrospective review of patients with EBOT treated in or referred to our institutions and a centralized, histological review by a reference pathologist. Data on the clinical characteristics, management (surgical and medical), and oncologic outcomes of patients were required for inclusion.\nResults\nForty-eight patients were identified. Median age was 52 years (range 14-89). Fourteen patients underwent a conservative surgery and 32 a bilateral salpingo-oophorectomy (unknown in 2 cases). Two patients had bilateral tumors. Forty-three patients had stage I disease, and five patients had stage II disease (10%). Stromal microinvasion and intraepithelial carcinoma was observed in 6 (12%) and 13 (27%) patients respectively. Endometriosis was histologically associated in 12 patients (25%). Synchronous endometrial disease was found in 7 (24%) of 29 patients with endometrial histological evaluation. The median follow-up was 72 months (range 6-146). Two patients developed a recurrence after cystectomy in form of borderline disease (5%). No death related to EBOT occurred.\nConclusions\nPeritoneal restaging surgery should be performed if not realized initially, because 5% of EBOTS are diagnosed at stage II–III. Fertility-sparing surgery seems a safe option in selected patients. Because synchronous endometrial diseases, including endometrial carcinoma are frequent, systematic hysterectomy (or endometrial sampling in case of fertility-sparing surgery) is mandatory. Prognosis is generally excellent. Recurrence is a rare event (6%), but it can occur in the form of invasive disease.\nSimilar content being viewed by others\nReferences\nKurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs, 4th Vol. 5th edn. 2020.\nFischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist. 2012;17(12):1515–33. https://doi.org/10.1634/theoncologist.2012-0139.\nUzan C, Berretta R, Rolla M, et al. Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol. 2012;21(3):178–84. https://doi.org/10.1016/j.suronc.2012.02.002.\nBell DA, Scully RE. Atypical and borderline endometrioid adenofibromas of the ovary. A report of 27 cases. Am J Surg Pathol. 1985;9(3):205–14. https://doi.org/10.1097/00000478-198503000-00004.\nBell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol. 2000;24(11):1465–79.\nYokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer. 2006;94(11):1586–91. https://doi.org/10.1038/sj.bjc.6603139.\nZheng JS, Ji ZJ, Yong LZ, et al. Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours. BMC Cancer. 2018;18(1):1160. https://doi.org/10.1186/s12885-018-5091-1.\nNakagawa E, Abiko K, Kido A, et al. Four cases of endometrioid borderline ovarian tumour: case reports and literature review. BJR Case Rep. 2017;4(1):20170062. https://doi.org/10.1259/bjrcr.20170062.\nRoth LM, Czernobilsky B, Langley FA. Ovarian endometrioid adenofibromatous and cystadenofibromatous tumors: benign, proliferating, and malignant. Cancer. 1981;48(8):1838–45. https://doi.org/10.1002/1097-0142(19811015)48:8%3c1838::aid-cncr2820480822%3e3.0.co;2-r.\nRoth LM, Emerson RE, Ulbright TM. Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol. 2003;27(9):1253–9. https://doi.org/10.1097/00000478-200309000-00009.\nRussell P. The pathological assessment of ovarian neoplasms. II: The proliferating “epithelial” tumours. Pathology (Phila). 1979;11(2):251–82. https://doi.org/10.3109/00313027909061951.\nSnyder RR, Norris HJ, Tavassoli F. Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol. 1988;12(9):661–71. https://doi.org/10.1097/00000478-198809000-00002.\nYüksel D, Çakır C, Kimyon Cömert G, et al. Uncommon borderline ovarian tumours: A clinicopathologic study of seventeen patients. J Turk Ger Gynecol Assoc. 2019;20(4):224–30. https://doi.org/10.4274/jtgga.galenos.2018.2018.0098.\nKliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol. 1986;68(3):338–44. https://doi.org/10.1097/00006250-198609000-00009.\nVo TM, Duong KA, Tran LT, Bui TC. Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam. J Obstet Gynaecol Res. 2019;45(10):2055–61. https://doi.org/10.1111/jog.14072.\nJi H, Yliskoski M, Anttila M, Syrjänen K, Saarikoski S. Management of stage-I borderline ovarian tumors. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 1996;54(1):37–44. https://doi.org/10.1016/0020-7292(96)02674-4.\nZhang W, Jia S, Xiang Y, Yang J, Jia C, Leng J. Comparative study of endometrioid borderline ovarian tumor with and without endometriosis. J Ovarian Res. 2018;11(1):67. https://doi.org/10.1186/s13048-018-0440-x.\nRicotta G, Maulard A, Genestie C, et al. Brenner borderline ovarian tumor: a case series and literature review. Ann Surg Oncol. 2021;28(11):6714–20. https://doi.org/10.1245/s10434-021-09879-y.\nRicotta G, Maulard A, Candiani M, et al. Clear cell borderline ovarian tumor: clinical characteristics, prognosis, and management. Ann Surg Oncol. 2022;29(2):1165–70. https://doi.org/10.1245/s10434-021-10776-7.\nAuthor information\nAuthors and Affiliations\nContributions\nPM and SG conceived the study. SG, PM, and AM undertook surgical management. GR performed data acquisition. GR and PM performed analyses. GR and PM wrote the manuscript. All authors reviewed the manuscript, approved the final version, and are accountable for all aspects of the work.\nCorresponding author\nEthics declarations\nThe authors declare that they have no conflict of interest.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nRicotta, G., Maulard, A., Candiani, M. et al. Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements. Ann Surg Oncol 29, 5894–5903 (2022). https://doi.org/10.1245/s10434-022-11893-7\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1245/s10434-022-11893-7","source_license":"public-domain-us","license_restricted":false}